Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2-amino-3-benzoylbenzeneacetamide
2. Nevanac
1. 78281-72-8
2. Nevanac
3. 2-(2-amino-3-benzoylphenyl)acetamide
4. 2-amino-3-benzoylbenzeneacetamide
5. Ahr-9434
6. Ilevro
7. Al 6515
8. Al-6515
9. Ahr 9434
10. Benzeneacetamide, 2-amino-3-benzoyl-
11. Chebi:75922
12. 0j9l7j6v8c
13. Ahr 9434;al 6515
14. Ncgc00185741-01
15. Dsstox_cid_28564
16. Dsstox_rid_82836
17. Dsstox_gsid_48638
18. Nepafenac [usan]
19. Amfenac Amide
20. Smr002529588
21. Cas-78281-72-8
22. Nepafenaco
23. Nepafenacum
24. Unii-0j9l7j6v8c
25. Nepafena
26. Nepafenac [usan:inn:ban:jan]
27. Nevanac (tn)
28. Mfcd08067732
29. 2-(2-amino-3-benzoyl-phenyl)acetamide
30. 2-[2-amino-3-(benzoyl)phenyl]acetamide
31. Nepafenac [inn]
32. Nepafenac [jan]
33. Nepafenac [mi]
34. Nepafenac [vandf]
35. Nepafenac [mart.]
36. Nepafenac [usp-rs]
37. Nepafenac [who-dd]
38. Chembl1021
39. Schembl93835
40. Nepafenac [ema Epar]
41. Mls003915618
42. Mls004774140
43. Mls006010644
44. Nepafenac (jan/usan/inn)
45. Gtpl7564
46. Nepafenac [orange Book]
47. Dtxsid0048638
48. Nepafenac, >=98% (hplc)
49. 2-amino-3-benzoyl-phenylacetamide
50. Hms3654p07
51. Hms3884e07
52. Act02914
53. Amy10899
54. Bcp21333
55. Ex-a1350
56. Wzb81453
57. Zinc5162311
58. Tox21_112985
59. Bdbm50228731
60. S1255
61. Stl451069
62. Akos005146108
63. Tox21_112985_1
64. Ac-6949
65. Ccg-267004
66. Cs-0899
67. Db06802
68. Ncgc00185741-02
69. 2-(2-amino-3-benzoyl-phenyl)-acetamide
70. As-19176
71. Hy-17357
72. 2-amino-3-benzoylbenzeneacetamide;nepafenac
73. Ft-0603701
74. N0932
75. Sw219197-1
76. 2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide
77. A26218
78. D05143
79. Ab01274763-01
80. Ab01274763_02
81. 281n728
82. A890381
83. Q684379
84. Sr-01000931908
85. J-507774
86. Sr-01000931908-2
87. Brd-k04112579-001-02-1
Molecular Weight | 254.28 g/mol |
---|---|
Molecular Formula | C15H14N2O2 |
XLogP3 | 1.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 254.105527694 g/mol |
Monoisotopic Mass | 254.105527694 g/mol |
Topological Polar Surface Area | 86.2 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 337 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Nevanac |
Drug Label | NEVANAC (nepafenac ophthalmic suspension) 0.1% is a sterile, topical, nonsteroidal anti-inflammatory (NSAID) prodrug for ophthalmic use. Each mL of NEVANAC suspension contains 1 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-ben... |
Active Ingredient | Nepafenac |
Dosage Form | Suspension/drops |
Route | Ophthalmic |
Strength | 0.1% |
Market Status | Prescription |
Company | Alcon Pharms |
2 of 2 | |
---|---|
Drug Name | Nevanac |
Drug Label | NEVANAC (nepafenac ophthalmic suspension) 0.1% is a sterile, topical, nonsteroidal anti-inflammatory (NSAID) prodrug for ophthalmic use. Each mL of NEVANAC suspension contains 1 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-ben... |
Active Ingredient | Nepafenac |
Dosage Form | Suspension/drops |
Route | Ophthalmic |
Strength | 0.1% |
Market Status | Prescription |
Company | Alcon Pharms |
For the treatment of pain and inflammation associated with cataract surgery.
FDA Label
Nevanac is indicated for:
- prevention and treatment of postoperative pain and inflammation associated with cataract surgery;
- reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours postdose, respectively, following bilateral topical ocular TID dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 0.104 ng/ml and 0.422 0.121 ng/ml, respectively, following ocular administration.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
S01BC10
S01BC10
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01B - Antiinflammatory agents
S01BC - Antiinflammatory agents, non-steroids
S01BC10 - Nepafenac
Absorption
Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).
Route of Elimination
After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine.
Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation.
Nepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity.
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25528
Submission : 2014-12-17
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-09-22
Pay. Date : 2014-07-11
DMF Number : 28432
Submission : 2014-07-22
Status : Active
Type : II
NDC Package Code : 53296-0099
Start Marketing Date : 2009-12-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28205
Submission : 2015-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22636
Submission : 2009-03-19
Status : Active
Type : II
NDC Package Code : 64181-0019
Start Marketing Date : 2005-08-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (6kg/6kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30593
Submission : 2016-06-21
Status : Active
Type : II
Date of Issue : 2022-06-22
Valid Till : 2025-07-28
Written Confirmation Number : WC-0117
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30594
Submission : 2016-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17812
Submission : 2004-11-03
Status : Active
Type : II
Registration Number : 222MF10160
Registrant's Address : Hauptstrasse 171, CH-4416 Bubendorf, Switzerland
Initial Date of Registration : 2010-05-31
Latest Date of Registration : --
NDC Package Code : 58567-104
Start Marketing Date : 2014-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Sweden
Brand Name : NEVANAC
Dosage Form : EYE DROPS, SUSPENSION
Dosage Strength : 3 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : NEVANAC
Dosage Form : EYE DROPS, SUSPENSION
Dosage Strength : 1 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Nevanac
Dosage Form : Nepafenac 5Ml 1 Mg/Ml Solution Ophthalmic Use
Dosage Strength : EYE DROPS 5 ml 1 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Nevanac
Dosage Form : Eye drops, suspension
Dosage Strength : 1 mg/ml
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Nevanac
Dosage Form : Eye drops, suspension
Dosage Strength : 3 mg/ml
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Nevanac
Dosage Form : Susp Opht
Dosage Strength : 1mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Nevanac
Dosage Form : Susp Opht
Dosage Strength : 3mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Nevanac
Dosage Form : Eye drops, suspension
Dosage Strength : 1 mg/ml
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : EYE DROPS
Dosage Strength : 0.3%
Packaging : 5 Ml/Bottle
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Norway
Brand Name : Nevanac
Dosage Form : Eye drops, suspension
Dosage Strength : 1 mg/ml
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Nepafenac manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nepafenac, including repackagers and relabelers. The FDA regulates Nepafenac manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nepafenac API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nepafenac manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nepafenac supplier is an individual or a company that provides Nepafenac active pharmaceutical ingredient (API) or Nepafenac finished formulations upon request. The Nepafenac suppliers may include Nepafenac API manufacturers, exporters, distributors and traders.
click here to find a list of Nepafenac suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nepafenac DMF (Drug Master File) is a document detailing the whole manufacturing process of Nepafenac active pharmaceutical ingredient (API) in detail. Different forms of Nepafenac DMFs exist exist since differing nations have different regulations, such as Nepafenac USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nepafenac DMF submitted to regulatory agencies in the US is known as a USDMF. Nepafenac USDMF includes data on Nepafenac's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nepafenac USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nepafenac suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nepafenac Drug Master File in Japan (Nepafenac JDMF) empowers Nepafenac API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nepafenac JDMF during the approval evaluation for pharmaceutical products. At the time of Nepafenac JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nepafenac suppliers with JDMF on PharmaCompass.
A Nepafenac written confirmation (Nepafenac WC) is an official document issued by a regulatory agency to a Nepafenac manufacturer, verifying that the manufacturing facility of a Nepafenac active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nepafenac APIs or Nepafenac finished pharmaceutical products to another nation, regulatory agencies frequently require a Nepafenac WC (written confirmation) as part of the regulatory process.
click here to find a list of Nepafenac suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nepafenac as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nepafenac API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nepafenac as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nepafenac and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nepafenac NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nepafenac suppliers with NDC on PharmaCompass.
Nepafenac Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nepafenac GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nepafenac GMP manufacturer or Nepafenac GMP API supplier for your needs.
A Nepafenac CoA (Certificate of Analysis) is a formal document that attests to Nepafenac's compliance with Nepafenac specifications and serves as a tool for batch-level quality control.
Nepafenac CoA mostly includes findings from lab analyses of a specific batch. For each Nepafenac CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nepafenac may be tested according to a variety of international standards, such as European Pharmacopoeia (Nepafenac EP), Nepafenac JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nepafenac USP).
LOOKING FOR A SUPPLIER?